Skip to main content

Table 5 Demographic and clinical characteristics of the responders and non-responders of IFX with CMV infection

From: Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience

Characteristics Responders with CMV infection (n = 6) Non-responders with CMV infection (n = 5) p value
Sex (men/women), n (%) 4 (66.7)/2 (33.3) 2 (40.0)/3 (60.0) 0.38
Age (years)* 50.8 ± 16.2 41.4 ± 17.2 0.42
Disease duration (years)* 4.5 ± 4.8 10.2 ± 9.6 0.32
Modified Truelove and Witts severity index* 8.3 ± 1.7 12.4 ± 2.2 0.02
Mayo score (endoscopy)* 2.8 ± 0.4 3.0 ± 0.0 0.37
Extent of disease    
  Left-side type, n (%) 2 (33.3) 0 (0.0) 0.15
  Extensive colitis, n (%) 4 (66.7) 5 (100.0)
Concomitant medications    
  Corticoteroids, n (%) 0 (0.0) 1 (20.0) 0.25
  Azathioprine/Mercaptopurine, n (%) 3 (50.0) 2 (40.0) 0.74
  Tacrolimus, n (%) 1 (16.7) 4 (80.0) 0.04
  1. IFX: infliximab, CR: clinical remission, CRP: C-reactive protein.
  2. Result reported as number (%) of patients or *mean ± standard deviation.